Enhancing quality of life and functional capacity in heart failure patients with iron deficiency: A regional cross-sectional study on intravenous iron therapy in Vietnam.

Intravenous iron supplementation, particularly ferric carboxymaltose (FCM), has emerged as an effective therapeutic strategy for correcting iron deficiency (ID) in patients with heart failure with reduced ejection fraction (HFrEF). However, the enhancement related to the quality of life (QoL) and functional capacity remains unclear, specifically in the Vietnam population. This study assesses the enhancement of QoL and functional capacity in intravenous FCM therapy in heart failure patients with ID.